521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial

Kristeleit, Rebecca; Gourley, C.; Roux, René L.; Hall, Marcia; Devlin, M-J.; Nirsimloo, Rachel; Kounnis, Valentinos; Hughes, Lucy; Counsell, Nicholas; Farrelly, Laura; Miller, Robert F.

doi:10.1016/j.annonc.2022.07.649

Cited by 21 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 1-year duration of response rate was 47.7% (95% CI 14.1% to 75.6%) and after a median follow-up of 2.1 years the median progression-free survival was 12.2 weeks (95% CI 5.90 to 32.9 weeks) and median overall survival was 71.9 weeks (95% 29.1 to 137.6 weeks). 33 These results support further investigation of pembrolizumab and other immune checkpoint inhibitors in…”

Section: Reviewsupporting

confidence: 69%

New therapies for clear cell ovarian carcinoma

Stewart

Cunningham

Banerjee

2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

Ovarian clear cell carcinoma is a rare subtype of epithelial ovarian cancer with unique clinicopathological features. The most common genetic aberration observed is loss of functionARID1Amutations. Advanced and recurrent ovarian clear cell carcinoma is characterized by resistance to standard-of-care cytotoxic chemotherapy and a poor prognosis. Despite the distinct molecular features of ovarian clear cell carcinoma, current treatments for this subtype of epithelial ovarian cancer are based on clinical trials which predominantly recruited patients with high grade serous ovarian carcinoma. These factors have encouraged researchers to develop novel treatment strategies specifically for ovarian clear cell carcinoma which are currently being tested in the context of clinical trials. These new treatment strategies currently focus on three key areas: immune checkpoint blockade, targeting angiogenesis, and exploitingARID1Asynthetic lethal interactions. Rational combinations of these strategies are being assessed in clinical trials. Despite the progress made in identifying new treatments for ovarian clear cell carcinoma, predictive biomarkers to better define those patients likely to respond to new treatments remain to be elucidated. Additional future challenges which may be addressed through international collaboration include the need for randomized trials in a rare disease and establishing the relative sequencing of these novel treatments.

show abstract

Section: Reviewsupporting

confidence: 69%

New therapies for clear cell ovarian carcinoma

Stewart

Cunningham

Banerjee

2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Given the poor outcome of advanced stage clear cell carcinoma of the cervix ( Zong et al, 2020 Apr ), known to be resistant to chemotherapy and radiotherapy, and the relatively high response rates to immunotherapy of clear cell carcinoma for other gynecological sites (ovary and endometrium) ( Kristeleit et al, 2022 ), we proposed for this young patient a window-of-opportunity neoadjuvant immunotherapy with anti-PD1 Nivolumab.…”

Section: Case Reportmentioning

confidence: 99%

“…Gene-expression profile of ovarian CCC identified two subsets: one non-immune enriched with good outcome and one immune enriched that has poor outcome ( Ye et al, 2022 May ). Anecdotal reports from several trials with PD1 blockade suggested that gynecological CCC (ovary and endometrium) could benefit from immunotherapy ( Bogani et al, 2022 Mar , Kristeleit et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix

Courtès,

Kountouri,

Wang

et al. 2024

Gynecologic Oncology Reports

View full text Add to dashboard Cite

“…This study reported an overall response rate of 25% and disease control rate of 45.8% with median overall survival of 71 weeks. 49 BrUOG 354 explored the activity of the PD-1 inhibitor nivolumab with and without ipilimumab (anti-CTLA4) in ovarian or extra-renal clear-cell pathologies; the stage 1 results of this study reported an overall response rate of 26.6% ( n = 4/15) in the combination arm compared to 16.7% ( n = 2/12) for nivolumab alone and so stage 2 will focus on dual treatment with nivolumab and ipilimumab. 50 In comparison to these two studies, MOCCA was a phase II study exploring the role of the PD-L1 inhibitor durvalumab against physicians choice of chemotherapy; this study was negative with an overall response rate to durvalumab of 10.7% and no significant difference in OS.…”

Section: Clear-cell Ovarian Cancermentioning

confidence: 99%

Disparity in the era of personalized medicine for epithelial ovarian cancer

Devlin

Miller

2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

The treatment of high-grade serous ovarian cancer and high-grade endometrioid ovarian cancer has seen significant improvements in recent years, with BRCA1/2 and homologous recombination status guiding a personalized approach which has resulted in improved patient outcomes. However, for other epithelial ovarian cancer subtypes, first-line treatment remains unchanged from the platinum–paclitaxel trials of the early 2000s. In this review, we explore novel therapeutic approaches being adopted in the treatment of clear cell, mucinous, carcinosarcoma and low-grade serous ovarian cancer and the biological rational behind them. We discuss why such disparities exist, the challenges faced in conducting dedicated trials in these rarer histologies and look towards new approaches being adopted to overcome them.

show abstract

521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial

Cited by 21 publications

References 0 publications

New therapies for clear cell ovarian carcinoma

New therapies for clear cell ovarian carcinoma

Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix

Disparity in the era of personalized medicine for epithelial ovarian cancer

Contact Info

Product

Resources

About